T3 Companies
STLN icon

T3 Companies’s Starling Oncology STLN Stock Holding History

T3 Companies’s Portfolio STLN Stock Details STLN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q3 		$408K Sell
64,500
-15,500
-19% -$92.6K 0.39% 53
2026
Q2 		$434K Sell
80,000
-31,900
-29% -$134K 0.46% 47
2026
Q1 		$344K Sell
111,900
-89,200
-44% -$274K 0.45% 40
2025
Q4 		$716K Buy
+201,100
New +$746K 0.89% 22

Other funds holding STLN

Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.92T AUM 36.1% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $608B AUM 32.77% 1-Year Est. Return
Creative Planning
Creative Planning Overland Park, Kansas $179B AUM 16.96% 1-Year Est. Return
Kingswood Wealth Advisors
Kingswood Wealth Advisors San Diego, California $2.6B AUM 27.46% 1-Year Est. Return
State of Wyoming
State of Wyoming Cheyenne, Wyoming $1.29B AUM 32.25% 1-Year Est. Return
Wealth Enhancement Advisory Services
Wealth Enhancement Advisory Services Plymouth, Minnesota $67.3B AUM 21.9% 1-Year Est. Return
Deutsche Bank
Deutsche Bank Frankfurt Am Main Ge, Germany $362B AUM 34.89% 1-Year Est. Return
Allspring Global Investments
Allspring Global Investments Charlotte, North Carolina $64.1B AUM 28.9% 1-Year Est. Return
Barclays
Barclays London, United Kingdom $500B AUM 36.84% 1-Year Est. Return
Russell Investments Group
Russell Investments Group London, United Kingdom $114B AUM 33.83% 1-Year Est. Return

T3 Companies's STLN Position: Q3 2026 in Review

T3 Companies reduced its Starling Oncology (STLN) stake by 19% in Q3 2026, selling an estimated $92.6K and leaving 64,500 shares worth $408K. The position accounts for 0.39% of the portfolio, ranked #53.

T3 Companies first reported a position in STLN in Q4 2025 and has held it in 4 quarters since. The position peaked at $716K in Q4 2025. 37 funds tracked by Wall St. Rank hold STLN as of Q3 2026.

  • T3 Companies held 64,500 shares of Starling Oncology worth $408K as of Q3 2026.
  • T3 Companies sold 15,500 Starling Oncology shares in Q3 2026, an estimated $92.6K.
  • Starling Oncology made up 0.39% of T3 Companies's portfolio in Q3 2026, its #53 holding.
  • T3 Companies first reported a position in Starling Oncology in Q4 2025 and has held it in 4 quarters since.
  • T3 Companies's Starling Oncology position peaked at $716K in Q4 2025.
  • 37 funds tracked by Wall St. Rank held Starling Oncology as of Q3 2026.

Based on T3 Companies's 13F filing for Q3 2026, filed 22 Oct 2026.